Neutral
Pfizer stock declines 1.14% to $27.80 amid revenue guidance increase
Pfizer's stock experienced a 1.14% decline to $27.80 on October 2, 2026, following the company's announcement of a $500 million increase in its full-year 2026 revenue guidance. Despite the guidance raise, the stock remains below its 52-week high of $29.21, indicating investor caution.
Key points
- Pfizer's Q2 2026 revenue guidance raised by $500 million to $60.5–62.5 billion.
- Adjusted diluted EPS for Q2 2026 reported at $0.77, surpassing consensus estimates.
- Stock trading below 52-week high of $29.21, closing at $27.80 on October 2, 2026.
Sources
AI-generated from public news sources. Not financial advice.
